ES2204613T3 - Androgenos 7-alfa alquilo oralmente activos. - Google Patents

Androgenos 7-alfa alquilo oralmente activos.

Info

Publication number
ES2204613T3
ES2204613T3 ES00936686T ES00936686T ES2204613T3 ES 2204613 T3 ES2204613 T3 ES 2204613T3 ES 00936686 T ES00936686 T ES 00936686T ES 00936686 T ES00936686 T ES 00936686T ES 2204613 T3 ES2204613 T3 ES 2204613T3
Authority
ES
Spain
Prior art keywords
alkyl
ethyl
compound
ethenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00936686T
Other languages
English (en)
Spanish (es)
Inventor
Jaap Louw Van Der
Dirk Leysen
Roberta Buma Bursi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2204613T3 publication Critical patent/ES2204613T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES00936686T 1999-04-06 2000-03-31 Androgenos 7-alfa alquilo oralmente activos. Expired - Lifetime ES2204613T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201070 1999-04-06
EP99201070 1999-04-06

Publications (1)

Publication Number Publication Date
ES2204613T3 true ES2204613T3 (es) 2004-05-01

Family

ID=8240066

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00936686T Expired - Lifetime ES2204613T3 (es) 1999-04-06 2000-03-31 Androgenos 7-alfa alquilo oralmente activos.

Country Status (10)

Country Link
US (2) US6756366B1 (enExample)
EP (1) EP1212345B1 (enExample)
JP (1) JP2002541153A (enExample)
AT (1) ATE246703T1 (enExample)
AU (1) AU5209600A (enExample)
CO (1) CO5160345A1 (enExample)
DE (1) DE60004377T2 (enExample)
ES (1) ES2204613T3 (enExample)
PE (1) PE20010029A1 (enExample)
WO (1) WO2000059920A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059920A2 (en) * 1999-04-06 2000-10-12 Akzo Nobel N.V. Orally active 7.alpha.-alkyl androgens
DE10104327A1 (de) * 2001-01-24 2002-07-25 Schering Ag 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate
CA2472379C (en) * 2002-01-21 2010-05-25 Akzo Nobel N.V. Process for the preparation of 7.alpha.-methylsteroids
GB0304927D0 (en) * 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
PE20050677A1 (es) 2003-12-22 2005-10-04 Akzo Nobel Nv Esteroides con perfil androgenico y progestagenico mixto
JP5524177B2 (ja) * 2008-04-09 2014-06-18 フェリン ファーマシューティカルズ インコーポレイテッド ほてりのためのステロイド治療
CN103347525A (zh) * 2010-12-15 2013-10-09 哈博生物科学公司 制备3α-氧取代的甾族化合物的方法及化合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755689A (fr) * 1969-09-03 1971-03-03 Upjohn Co Procede de fabrication de nouvelles 7 beta-alkyl-19- nortestosterones
US5342834A (en) * 1989-04-07 1994-08-30 The Population Council, Inc. Method for androgen supplementation
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
US6037339A (en) * 1993-02-08 2000-03-14 Akzo Nobel N.V. C-11 substituted steroids for treating menopausal complaints
AU671706B2 (en) * 1993-03-05 1996-09-05 Akzo N.V. Use of a Pregnane Derivative
IL113816A (en) * 1994-06-08 1998-12-06 Akzo Nobel Nv Pharmaceutical compositions containing desogestrel their preparation and use
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
HU223943B1 (hu) * 1995-06-22 2005-03-29 Akzo Nobel N.V. Dezogesztrelt tartalmazó, szárazon granulált, sajtolt tabletták és előállításuk
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US5998639A (en) * 1995-11-06 1999-12-07 Akzo Nobel, N.V. Sulfatation of estrogen mixtures
ZA968873B (en) * 1995-11-06 1997-05-28 Akzo Nobel Nv Isomerisation of equillin
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
US6506390B2 (en) * 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
IL123195A (en) * 1997-02-21 2002-11-10 Akzo Nobel Nv Steroid compounds with anti-pregnancy activity and against bone thinning, preparation and pharmaceutical preparations containing them
BR9808803A (pt) * 1997-05-16 2000-07-18 Akzo Nobel Nv Derivado de 20-aralquil-5alfa-pregnano, uso do mesmo, e, composição farmacêutica
WO1998055498A1 (en) * 1997-06-04 1998-12-10 Akzo Nobel N.V. 17β-ALLYLOXY(THIO)ALKYL-ANDROSTANE DERIVATIVES FOR THE MODULATION OF MEIOSIS
ES2152065T3 (es) * 1997-09-23 2001-01-16 Akzo Nobel Nv Unidades de dosificado de esteroides con un recubrimiento estanco a los esteroides.
US6080773A (en) * 1997-10-14 2000-06-27 Akzo Nobel, N.V. Benzylamine derivatives which are useful in treating psychiatric disorders
BR9814136A (pt) * 1997-11-14 2000-10-03 Akzo Nobel Nv Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.
WO1999032506A1 (en) * 1997-12-18 1999-07-01 Akzo Nobel N.V. 17β-ARYL (ARYLMETHYL) OXY(THIO)ALKYL -ANDROSTANE DERIVATIVES
NZ506465A (en) * 1998-02-26 2003-08-29 Akzo Nobel Nv Derivatives of azetidine and pyrrolidine
WO1999067271A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Testosterone derivative
AU759344B2 (en) * 1998-12-11 2003-04-10 Akzo Nobel N.V. 22S-hydroxycholesta-8, 14-diene derivatives with meiosis regulating activity
US6498153B1 (en) * 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
DK1163258T3 (da) * 1999-03-09 2003-03-31 Akzo Nobel Nv Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis
WO2000059920A2 (en) * 1999-04-06 2000-10-12 Akzo Nobel N.V. Orally active 7.alpha.-alkyl androgens
TW548277B (en) * 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
MXPA02001831A (es) * 1999-09-06 2002-10-23 Akzo Nobel Nv Esteroides estrogenicos no aromaticos con un sustituyente de hidrocarburo en posicion 11.
PL202999B1 (pl) * 1999-12-02 2009-08-31 Organon Nv Androgeny zawierające pierścień cyklopropanowy w pozycjach 14, 15 i zastosowanie takich androgenów
AU2001254710A1 (en) * 2000-03-27 2001-10-08 Akzo Nobel N.V. Non-steroidal, tetracyclic compounds for estrogen-related treatments
IL154408A0 (en) * 2000-08-23 2003-09-17 Akzo Nobel Nv 10-ARYL-11-H BENZO [b] FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE

Also Published As

Publication number Publication date
JP2002541153A (ja) 2002-12-03
ATE246703T1 (de) 2003-08-15
CO5160345A1 (es) 2002-05-30
WO2000059920A3 (en) 2001-02-15
WO2000059920A2 (en) 2000-10-12
DE60004377T2 (de) 2004-06-09
DE60004377D1 (de) 2003-09-11
US6756366B1 (en) 2004-06-29
EP1212345A2 (en) 2002-06-12
AU5209600A (en) 2000-10-23
EP1212345B1 (en) 2003-08-06
PE20010029A1 (es) 2001-01-26
US20040209853A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
ES2213596T3 (es) Androgenos con una actividad oral.
US7196074B2 (en) Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof
ES2258037T3 (es) Androgenos sustituidos con 14,15-beta-metilen.
ES2204613T3 (es) Androgenos 7-alfa alquilo oralmente activos.
JP2010529153A (ja) １７β−シアノ−１９−ノル−アンドロスタ−４−エン誘導体、その使用、及び当該誘導体を含む医薬
US6881728B1 (en) 14-β, 17-α-hydroxymethylandrostane derivatives as androgens
HUT73238A (en) 15,15-dialkyl-substituted derivatives of estradiol and pharmaceutical compositions containing the same
EP1846434B1 (en) NANDROLONE 17ß-CARBONATES
JP4279552B2 (ja) 新規アンドロゲンとしてのメチレンステロイド
US20040059140A1 (en) 14(15)-unsaturated 15- and/or 16-substituted androgens with mixed androgen-progrestational profile
AU2002258664B2 (en) Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17-esters thereof